Chemed Corporation Valuation – Initial Coverage $CHE

Benjamin Graham taught that Intelligent Investors must do a thorough fundamental analysis of investment opportunities to determine their intrinsic value and inherent risk.  This is best done by utilizing a systematic approach to analysis that will provide investors with a sense of how a specific company compares to another company or by reviewing the 10 Stocks for Using A Benjamin Graham Value Investing Strategy – December 2016.  By using the ModernGraham method one can review a company’s historical accomplishments and determine an intrinsic value that can be compared across industries.  What follows is a stock analysis showing a specific look at how Chemed Corporation (CHE) fares in the ModernGraham valuation model.

Company Profile (obtained from Google Finance): Chemed Corporation operates and divests subsidiaries engaged in diverse business activities. The Company operates its business in two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS segment provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers. VITAS segment provides hospice care to Medicare beneficiaries receiving their non-hospice healthcare services from health maintenance organizations (HMOs) under Medicare risk contracts. The Company and its subsidiaries also own training manuals, cost information, patient information and software source codes. A portion of its VITAS business is operated in the state of Florida. The Company’s Roto-Rooter segment provides plumbing, drain cleaning, water restoration and other related services to both residential and commercial customers.

CHE Chart

CHE data by YCharts

To read the details of this valuation, you must be logged in as a premium member. If you are not a premium member, please consider becoming one.

Premium members can view a full ModernGraham valuation of the company and have access to download a PDF version of the valuation for easy reference. Recent valuations of the components of the Dow Jones Industrial Average are available for free members, including this one of Microsoft Corporation.  In addition, here is a post detailing what can be found within each individual company’s valuation.


Downloadable PDF version of this valuation:

ModernGraham Valuation of CHE – December 2016

Stage 1: Is this company suitable for the Defensive Investor or the Enterprising Investor?

What kind of Intelligent Investor are you?

Defensive Investor; must pass 6 out of the following 7 tests.
1. Adequate Size of the Enterprise Market Cap > $2Bil $2,494,221,889 Pass
2. Sufficiently Strong Financial Condition Current Ratio > 2 0.79 Fail
3. Earnings Stability Positive EPS for 10 years prior Pass
4. Dividend Record Dividend Payments for 10 years prior Pass
5. Earnings Growth Increase of 33% in EPS in past 10 years using 3 year averages at beginning and end 113.73% Pass
6. Moderate PEmg Ratio PEmg < 20 25.97 Fail
7. Moderate Price to Assets PB Ratio < 2.5 OR PB*PEmg < 50 5.19 Fail
Enterprising Investor; must pass 4 out of the following 5 tests, or be suitable for the Defensive Investor.
1. Sufficiently Strong Financial Condition Current Ratio > 1.5 0.79 Fail
2. Sufficiently Strong Financial Condition Debt to NCA < 1.1 -2.97 Fail
3. Earnings Stability Positive EPS for 5 years prior Pass
4. Dividend Record Currently Pays Dividend Pass
5. Earnings Growth EPSmg greater than 5 years ago Pass

Stage 2: Determination of Intrinsic Value

EPSmg $5.87
MG Growth Estimate 7.21%
MG Value $134.66
Opinion Overvalued
MG Grade D
MG Value based on 3% Growth $85.18
MG Value based on 0% Growth $49.93
Market Implied Growth Rate 8.74%
Current Price $152.59
% of Intrinsic Value 113.31%

Chemed Corporation does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the low current ratio, high PEmg and PB ratios. The Enterprising Investor has concerns regarding the level of debt relative to the current assets. As a result, all value investors following the ModernGraham approach should explore other opportunities at this time or proceed cautiously with a speculative attitude.

As for a valuation, the company appears to be Overvalued after growing its EPSmg (normalized earnings) from $3.97 in 2012 to an estimated $5.87 for 2016. This level of demonstrated earnings growth does not support the market’s implied estimate of 8.74% annual earnings growth over the next 7-10 years. As a result, the ModernGraham valuation model, based on the Benjamin Graham value investing formula, returns an estimate of intrinsic value below the price.

At the time of valuation, further research into Chemed Corporation revealed the company was trading above its Graham Number of $66.94. The company pays a dividend of $0.98 per share, for a yield of 0.6% Its PEmg (price over earnings per share – ModernGraham) was 25.97, which was below the industry average of 32.29, which by some methods of valuation makes it one of the most undervalued stocks in its industry. Finally, the company was trading above its Net Current Asset Value (NCAV) of $-13.43.

Chemed Corporation scores quite poorly in the ModernGraham grading system, with an overall grade of D.

Stage 3: Information for Further Research

Net Current Asset Value (NCAV) -$13.43
Graham Number $66.94
PEmg 25.97
Current Ratio 0.79
PB Ratio 5.19
Current Dividend $0.98
Dividend Yield 0.64%
Number of Consecutive Years of Dividend Growth 8


Useful Links:

ModernGraham tagged articles Morningstar
Google Finance MSN Money
Yahoo Finance Seeking Alpha
GuruFocus SEC Filings

Most Recent Balance Sheet Figures

Balance Sheet Information 9/1/2016
Total Current Assets $132,959,000
Total Current Liabilities $167,457,000
Long-Term Debt $102,500,000
Total Assets $842,476,000
Intangible Assets $527,485,000
Total Liabilities $355,274,000
Shares Outstanding (Diluted Average) 16,559,000

Earnings Per Share History

Next Fiscal Year Estimate $6.63
Dec2015 $6.33
Dec2014 $5.57
Dec2013 $4.16
Dec2012 $4.62
Dec2011 $4.10
Dec2010 $3.55
Dec2009 $3.24
Dec2008 $2.88
Dec2007 $2.55
Dec2006 $1.90
Dec2005 $1.36
Dec2004 $1.12
Dec2003 -$0.18
Dec2002 -$0.13
Dec2001 -$0.63
Dec2000 $1.01
Dec1999 $0.93
Dec1998 $0.99
Dec1997 $1.51
Dec1996 $1.63

Earnings Per Share – ModernGraham History

Next Fiscal Year Estimate $5.87
Dec2015 $5.32
Dec2014 $4.67
Dec2013 $4.13
Dec2012 $3.97
Dec2011 $3.52
Dec2010 $3.09
Dec2009 $2.70
Dec2008 $2.28
Dec2007 $1.77
Dec2006 $1.19
Dec2005 $0.66
Dec2004 $0.28
Dec2003 -$0.02
Dec2002 $0.18
Dec2001 $0.48
Dec2000 $1.09

Recommended Reading:

Other ModernGraham posts about the company

None.  This is the first time ModernGraham has covered the company.

Other ModernGraham posts about related companies

Surgical Care Affiliates Inc Valuation – Initial Coverage $SCAI
Thermo Fisher Scientific Inc Valuation – December 2016 $TMO
Illumina Inc Valuation – Initial Coverage $ILMN
Thermo Fisher Scientific Inc Valuation – November 2016 $TMO
Waters Corporation Valuation – November 2016 $WAT
Align Technology Inc Valuation – August 2016 $ALGN
HCA Holdings Inc Valuation – August 2016 $HCA
Express Scripts Holding Co Valuation – August 2016 $ESRX
Universal Health Services Inc Valuation – August 2016 $UHS
Endo International PLC Valuation – August 2016 $ENDP


The author did not hold a position in any company mentioned in this article at the time of publication and had no intention of changing that position within the next 72 hours.  See my current holdings here.  This article is not investment advice; any reader should speak to a registered investment adviser prior to making any investment decisions.  ModernGraham is not affiliated with the company in any manner.  Please be sure to review our detailed disclaimer.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.